Market Overview

Sterne Agee Initiates Boston Scientific At Neutral

Share:
Related BSX
Boston Scientific Initiates Global Study To Assess EMBLEM Subcutaneous Implantable Defibrillator In Primary Prevention Patients With Low Ejection Fraction
New Data Demonstrate Greater Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System

Sterne Agee initiated coverage on shares of Boston Scientific (NYSE: BSX) with a Neutral rating.

The target price for Boston Scientific is set to $13.50.

Boston Scientific shares have surged 19.76% over the past 52 weeks, while the S&P 500 index has gained 17.38% in the same period.

Boston Scientific's shares dropped 1.07% to close at $12.97 yesterday.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Sterne AgeeInitiation Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters